Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coya Therapeutics (COYA) EBITDA (2022 - 2025)

Coya Therapeutics' EBITDA history spans 4 years, with the latest figure at -$2.4 million for Q3 2025.

  • For Q3 2025, EBITDA rose 45.4% year-over-year to -$2.4 million; the TTM value through Sep 2025 reached -$20.6 million, down 81.67%, while the annual FY2024 figure was -$17.2 million, 118.67% down from the prior year.
  • EBITDA for Q3 2025 was -$2.4 million at Coya Therapeutics, up from -$6.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $1.8 million in Q4 2023 and bottomed at -$7.7 million in Q1 2025.
  • The 4-year median for EBITDA is -$3.2 million (2023), against an average of -$3.4 million.
  • The largest annual shift saw EBITDA surged 191.25% in 2023 before it tumbled 323.57% in 2024.
  • A 4-year view of EBITDA shows it stood at -$2.0 million in 2022, then surged by 191.25% to $1.8 million in 2023, then crashed by 323.57% to -$4.1 million in 2024, then skyrocketed by 40.44% to -$2.4 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's EBITDA are -$2.4 million (Q3 2025), -$6.4 million (Q2 2025), and -$7.7 million (Q1 2025).